Percutanous management of tricuspid regurgitation: the "Achilles tendon" of transcatheter valve interventions

Abstract

Moderate-to-severe tricuspid insufficiency affects 1.6 million patients in the USA, resulting in increased morbidity and mortality and without safe and effective medical or surgical treatment options. The unique tricuspid valve anatomy, the presence of immediate adjacent anatomic landmarks at risk and the decreased blood pressure of flow complicate the development of effective transcatheter strategies. The HOVER trial will assess the safety and effectiveness of the CAVI approach with implantation of the Edwards, Sapien XT in the inferior vena cava.